Team:USTC CHINA

Based on the fundamental principles and technology of synthetic biology, our team aims at designing a brand-new immune system containing transdermal peptide that expresses genes and produces immune response simultaneously. To reach this goal, we need to build four kinds of engineering bacteria and find out effective immune stimulations and responses. Meanwhile, an appropriate reporting system guiding vaccination at different stages is also required to meet the demand of practical, safe and human-friendly production. The bacillus subtilis we use is WB800N. By Modifying it into four types of engineering bacteria, we combine the gene coding transdermal peptide with the gene coding LTB, HBsAg, reporter, and LC Luman-recruiting factor. Then, the engineering bacteria will produce mixture of fusion protein in the skin and activate immune response.

Due to the introducing of transdermal peptide and the simultaneous immune response with protein expression, our work has great advantages compared with the existing immune system for it is not only economical but also easy to operate. It is expected to become a promising new vaccine research field.

So far, we have successfully synthesize four kinds of plasmid, the sequence of which is proved to be correct. And we have managed to transform three plasmid from E. coli to Bacillus subtilis, and there is still one,GFP, in progress.

For the coming days, we plan to continue our transformation. Besides, experiments on the mice are also necessary to check the effect of our vaccine. And other tasks, such as human practice and the standardization of our parts, are in our future schedule.